LGI1-Antibody Encephalitis clinical trials at UCSF
1 research study open to eligible people
LGI1-antibody encephalitis is inflammation of the brain caused by antibodies that target LGI1. UCSF is conducting a clinical study of an antibody drug to record safety and immune response. UCSF is collecting medical data, blood samples, and imaging from enrolled adults.
Showing trials for
(PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
open to eligible people ages 12 years and up
The purpose of this study is to assess the efficacy, safety, PK, and PD of satralizumab in participants with NMDAR and LGI1 encephalitis.
San Francisco, California and other locations
Our lead scientists for LGI1-Antibody Encephalitis research studies include Jeffrey Gelfand.
Last updated: